Market Overview:
The global non-hematological cancer treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, growing awareness about various types of cancer treatments, and technological advancements in the field of oncology. The chemotherapy segment is expected to dominate the global non-hematological cancer treatment market during the forecast period. This can be attributed to the high efficacy and wide range of applications offered by chemotherapy drugs. The radiation therapy segment is projected to grow at a highest CAGR during the forecast period owing to its ability to target tumors directly and cause minimal damage to surrounding healthy tissues. In terms of application, hospitals are expected account for majority share in global non-hematological cancer treatment market during 2018–2030 owing higher adoption rates for advanced treatments such as radiation therapy.
Product Definition:
Non-Hematological Cancer Treatment is the term used to describe cancer treatments that do not involve the blood or bone marrow. This type of cancer treatment can include radiation therapy, chemotherapy, and surgery.
Chemotherapy:
Chemotherapy is a group of medical treatments used to treat cancer. Chemotherapies mainly focus on the immune system and aim to reduce or eliminate cancer through non-invasive methods. Some chemotherapy drugs may also have an adverse effect on the patient's health such as nausea, diarrhea, or hair loss among others; these are known as side effects.
Surgery:
Surgery is a general term for medical procedures that are performed to remove abnormal tissue or organ. There are various types of surgeries such as cardiovascular, neurovascular, orthopedic, gastrointestinal (GI), urological and others. The main function of these surgeries is to cure diseases and restore the normal functioning of body parts. Some other functions include cosmetic surgery which is used for improving physical appearance or changing physical characteristics (such as gender).
Application Insights:
The others segment held the largest share of the global non-hematological cancer treatment market in 2017. This segment includes oncology supportive care, palliative care and end-of-life care. The increasing prevalence of chronic diseases, such as cancer and other life-threatening conditions is expected to be a high rendering driver for this application segment during the forecast period.
In addition, an increase in healthcare awareness among patients regarding their treatment options is anticipated to boost growth during the forecast period. Increasing research & development activities by key industry players for developing new products specific to various applications is also expected to contribute towards market growth over the next eight years.
Oncology treatment centers accounted for a significant share of revenue in 2017 owing to factors such as an increase in demand from both public.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, availability of novel therapies, high healthcare expenditure and favorable government initiatives. For instance, in 2014 ‘Clinical Trial Matching Program’ was introduced as a part of the Cancer Therapy Unit (CTU) program by National Cancer Institute (NCI). CTU program matches patients with appropriate clinical trials based on their location and language preferences. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing number of approvals and commercialization of drugs in this region as well as increasing focus on quality healthcare services provided at affordable costs by governments there. In addition, rising awareness about cancer treatment options among people will drive regional growth during the forecast period.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the non-hematological cancer treatment market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This high incidence rate is expected to drive demand for various non-hematological cancer treatments over the forecast period.
- Rising awareness about different types of cancers: There has been a rise in awareness about different types of cancers in recent years due to increasing incidences and better diagnosis rates. This has led to an increase in demand for various non-hematological treatments across different geographies worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-Hematological Cancer Treatment Market Research Report
By Type
Chemotherapy, Surgery, Radiation Therapy, Others
By Application
Hospitals, Oncology Treatment Centre, Ambulatory Surgery Centers, Others
By Companies
Novartis, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Roche, Amgen, Astellas Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
210
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Non-Hematological Cancer Treatment Market Report Segments:
The global Non-Hematological Cancer Treatment market is segmented on the basis of:
Types
Chemotherapy, Surgery, Radiation Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Oncology Treatment Centre, Ambulatory Surgery Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Bristol-Myers Squibb
- Johnson & Johnson
- Roche
- Amgen
- Astellas Pharma
Highlights of The Non-Hematological Cancer Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Surgery
- Radiation Therapy
- Others
- By Application:
- Hospitals
- Oncology Treatment Centre
- Ambulatory Surgery Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-Hematological Cancer Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-hematological cancers are cancers that do not involve the blood or lymphatic system. Treatment for these types of cancer typically involves surgery, chemotherapy, and radiation therapy.
Some of the key players operating in the non-hematological cancer treatment market are Novartis, Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Roche, Amgen, Astellas Pharma.
The non-hematological cancer treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non-Hematological Cancer Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non-Hematological Cancer Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non-Hematological Cancer Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non-Hematological Cancer Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non-Hematological Cancer Treatment Market Size & Forecast, 2020-2028
4.5.1 Non-Hematological Cancer Treatment Market Size and Y-o-Y Growth
4.5.2 Non-Hematological Cancer Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Surgery
5.2.3 Radiation Therapy
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Oncology Treatment Centre
6.2.3 Ambulatory Surgery Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non-Hematological Cancer Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non-Hematological Cancer Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Surgery
9.6.3 Radiation Therapy
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Oncology Treatment Centre
9.10.3 Ambulatory Surgery Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Surgery
10.6.3 Radiation Therapy
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Oncology Treatment Centre
10.10.3 Ambulatory Surgery Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Surgery
11.6.3 Radiation Therapy
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Oncology Treatment Centre
11.10.3 Ambulatory Surgery Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Surgery
12.6.3 Radiation Therapy
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Oncology Treatment Centre
12.10.3 Ambulatory Surgery Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Surgery
13.6.3 Radiation Therapy
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Oncology Treatment Centre
13.10.3 Ambulatory Surgery Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non-Hematological Cancer Treatment Market: Competitive Dashboard
14.2 Global Non-Hematological Cancer Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Bristol-Myers Squibb
14.3.4 Johnson & Johnson
14.3.5 Roche
14.3.6 Amgen
14.3.7 Astellas Pharma
